(NASDAQ)
11.96
-0.44   (-3.55%)
Pre-market: 12.00 +0.0400 (+0.33%)
Volume (24h) Market Cap. Day Range 52w Range
1.62M 672.66M 11.41 - 12.78 4.46 - 16.60
Jan-25-21 07:00AM Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin LymphomaGlobeNewswire
Jan-20-21 09:47AM Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA NodZacks
Jan-19-21 07:00AM Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin LymphomaGlobeNewswire
Jan-07-21 07:00AM Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and CompanyGlobeNewswire
Jan-04-21 07:00AM Precision BioSciences to Present at the Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Dec-14-20 09:10AM Is DTIL A Good Stock To Buy Now?Insider Monkey
12:00PM Precision BioSciences Announces Executive Leadership ChangeGlobeNewswire
Dec-11-20 11:00AM Elo Life Systems Publishes the Most Detailed Genome Map in the Industry to Improve Quality and Supply Chain Stability of VanillaGlobeNewswire
Dec-04-20 06:30AM Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)GlobeNewswire
Nov-24-20 04:05AM Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewswire
Nov-20-20 07:00AM Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License AgreementPR Newswire
Nov-13-20 06:12AM Precision BioSciences, Inc. (NASDAQ:DTIL) Just Reported, And Analysts Assigned A US$17.33 Price TargetSimply Wall St.
Nov-10-20 08:45AM Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue EstimatesZacks
07:28AM Precision BioSciences: Q3 Earnings InsightsBenzinga
Nov-10-20 07:00AM Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire
Nov-03-20 12:30PM Earnings Preview: Precision BioSciences (DTIL) Q3 Earnings Expected to DeclineZacks
07:00AM Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020GlobeNewswire
Oct-15-20 07:00AM Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T PatentsGlobeNewswire
Oct-14-20 07:00AM Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs OfficerGlobeNewswire
Sep-28-20 07:00AM Precision BioSciences to Present at Upcoming Virtual Investor Conferences in OctoberGlobeNewswire
Sep-21-20 07:00AM Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple MyelomaGlobeNewswire
Sep-17-20 07:00AM Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid TumorsGlobeNewswire
Sep-15-20 07:21AM What Is The Ownership Structure Like For Precision BioSciences, Inc. (NASDAQ:DTIL)?Simply Wall St.
Sep-09-20 07:00AM Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple MyelomaGlobeNewswire
Sep-02-20 07:00AM Precision BioSciences to Present at Upcoming Virtual Investor Conferences in SeptemberGlobeNewswire
Aug-19-20 07:00AM Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell TherapyGlobeNewswire
Aug-13-20 10:35AM Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue EstimatesZacks
07:30AM Precision BioSciences: Q2 Earnings InsightsBenzinga
Aug-13-20 07:00AM Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire
Aug-06-20 12:30PM Earnings Preview: Precision BioSciences (DTIL) Q2 Earnings Expected to DeclineZacks
Aug-03-20 07:00AM Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor ConferencesGlobeNewswire
Jul-17-20 10:29AM Will Precision BioSciences (NASDAQ:DTIL) Spend Its Cash Wisely?Simply Wall St.
Jul-06-20 07:00AM Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus ProgramGlobeNewswire
Jul-05-20 04:33AM Hedge Funds Are Nibbling On Precision BioSciences, Inc. (DTIL)Insider Monkey
Jun-08-20 07:00AM Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple MyelomaGlobeNewswire
May-26-20 04:01AM Precision BioSciences to Present at Upcoming Investor ConferencesGlobeNewswire
May-18-20 06:34AM These Analysts Just Made A Decent Downgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) EPS ForecastsSimply Wall St.
May-15-20 08:52AM Precision BioSciences: Q1 Earnings InsightsBenzinga
08:15AM Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesZacks
May-15-20 07:00AM Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire
May-08-20 12:30PM Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks
May-07-20 07:00AM Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020GlobeNewswire
Apr-28-20 04:45AM Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual MeetingGlobeNewswire
Apr-27-20 12:31PM Will Precision BioSciences (DTIL) Report Negative Q1 Earnings? What You Should KnowZacks
Apr-15-20 07:00AM Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human ResourcesGlobeNewswire
Apr-07-20 07:00AM Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLLGlobeNewswire
Apr-02-20 02:54AM Gone: Triangle public companies lose $30 billion in value during 1Q 2020American City Business Journals
Mar-12-20 07:26AM Precision BioSciences, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest ReportSimply Wall St.
Mar-11-20 07:24AM One year after IPO, Durham firm eyes rapid advancement in 2020American City Business Journals
07:00AM Precision BioSciences Strengthens Board of Directors with Appointment of Geno GermanoGlobeNewswire
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Cap:    |  Volume (24h):